ABSTRACT
Results: In warfarin monitoring, the two local ISIs determined by the two local calibrators showed better consistency than uncorrected ISI, although they were inferior to the ISIs calibrated using the WHO method. Alternative calibration using calibration plasma from patients with liver cirrhosis instead of warfarinized plasma reduced the INR variability.

Conclusions: Local ISI determined by a commercial local calibrator improved INR standardization among thromboplastins. The alternative ISI calibration using liver-specific calibration plasma is expected to reduce INR variability for the evaluation of liver function.
Prothrombin time (PT) is widely used in monitoring warfarin, disseminated intravascular coagulation, and liver diseases. 1, 2 The international normalized ratio (INR)/international sensitivity index (ISI) system was introduced to standardize PT variation with the use of different thromboplastin reagents. 3, 4 The ISI of each thromboplastin represents a responsiveness to the reduction of coagulation factors. 5 The ISI varies according to the type of coagulometer and thromboplastins used. Recently, some manufacturers have provided "instrument-specific" and "thromboplastin-specific" ISIs, which have been shown to provide insufficiently standardized INR values. 6 Thus, determination of a local ISI for each combination of coagulometer and thromboplastin has been recommended for clinical laboratory practice. 7 Several methods of ISI calibration have been developed. 5 The World Health Organization (WHO) method for ISI calibration has not been feasible in most clinical laboratories Upon completion of this activity you will be able to:
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because plasma samples from 60 anticoagulated patients and 20 healthy controls are required. 5 The European Concerted Action on Anticoagulation (ECAA) has recommended a simplified WHO calibration method using 20 artificially depleted lyophilized plasma samples and seven normal lyophilized plasma samples with certified PT values. 8, 9 Direct INR was also proposed, which requires more than three pooled plasma samples and a normal pooled plasma sample, with certified INR values. 10 The establishment of a PT/INR line would allow for easy determination of a patient's INR values from his or her measured PT value without the need to measure ISI and mean normal prothrombin time (MNPT). 7 Although direct INR calibration methods may improve interlaboratory variability, 11 the implementation of direct INR in individual laboratories has been restricted due to a lack of certified plasma samples. Recently, commercially certified plasmas for the determination of local ISI have been introduced, with the advantages of simplifying procedures and improving INR accuracy. 12 The Clinical and Laboratory Standard Institute (CLSI) has recommended verification or assignment of a local ISI value to each combined thromboplastin/coagulometer system using certified plasmas in clinical laboratories. 7 However, different commercial certified plasmas may induce different ISI estimates, which may cause INR variation. 13 In addition to oral anticoagulant monitoring, INR has been used to assess disease severity in other coagulopathies, including liver disease. 1 While PT prolongation in patients treated with warfarin is a result of decreased factor II, VII, IX, and X levels, 14, 15 PT prolongation in patients with liver disease may be caused by deficiencies in all coagulation factors. 16 Since the patterns of coagulation factor deficiency differ according to the underlying disease, conventional ISI calibration using plasma from warfarin-treated patients may not yield consistent INR values among various thromboplastins as demonstrated previously. 17 Since the INR of patients with liver disease has been adopted in the model for the end-stage liver disease (MELD) score, which is generally used to prioritize patients for liver transplantation, 18 it is important to note that inconsistency in INR determination could lead to serious erroneous decisions, especially in recipient prioritization. Use of calibration plasma samples from patients with liver disease has been investigated as a method of reducing INR variation according to different thromboplastins. 1 Although several commercial local calibrators have been made available to clinical laboratories, there is limited information regarding the consistency of local ISIs determined using different commercial calibrators compared with the WHO method. 19, 20 
Materials and Methods
Study Population and Blood Samples
Blood was collected from 90 individuals on a stable warfarin dosage (41 men and 49 women; mean age, 65 years; age range, 32-90 years), 76 patients with liver cirrhosis (42 men and 34 women; mean age, 52 years; age range, 33-88 years), and 20 normal healthy controls (10 men and 10 women; mean age, 55 years; age range, 37-69 years). The patients on warfarin treatment showed a stable INR range (1.5-4.5), and their clinical conditions included prosthetic heart valves (n = 42), atrial fibrillation (n = 20), prosthetic heart valves with atrial fibrillation (n = 15), and thromboembolism (n = 13). Liver cirrhosis was diagnosed on the basis of clinical, laboratory, or radiologic findings. Exclusion criteria for cirrhotic patients were inherited bleeding or thrombotic disorders, warfarin or heparin use within 7 days of blood collection, or body weight less than 30 kg. The MELD score, used for the evaluation of cirrhosis severity, was calculated as follows: MELD score = 10[0.957 ln(creatinine, mg/dL) + 0.378 ln(bilirubin, mg/dL) + 1.12 ln(INR) + 0.643]. 18 Clinical and demographic data were collected from medical records. This study was approved by the Institutional Review Board of Seoul National University Hospital.
Peripheral blood samples were collected in 3.2% sodium citrate. Following centrifugation (1550g for 15 minutes) at room temperature, plasma was separated into aliquots and stored at -70°C until testing.
Reagents and Instruments
We used six commercial PT reagents ❚Table 1❚, including Innovin (lot number 539189; Siemens Healthcare Diagnostics, Marburg, Germany), RecombiPlasTin 2G (N0720740; Instrumentation Laboratory, Lexington, MA), Thromborel S (545480; Siemens Healthcare Diagnostics), PT-Fibrinogen HS Plus (N1017745; Beckman Coulter, Miami, FL), Neoplastine Cl Plus (107920; Diagnostica Stago, Asnieres, France), and PT-Fibrinogen (N0429644; Beckman Coulter). We arbitrarily used one lot (N0817013, ISI 1.03) of RecombiPlasTin 2G (Instrumentation Laboratory) as a reference thromboplastin to assign ISI values calibrated using the WHO method. 5 Plasma levels of coagulation factors II, V, VII, and X were determined using a one-stage clotting assay (HemosIL; Instrumentation Laboratory). All tests were performed on the ACL 3000 coagulation analyzer (Beckman Coulter, Fullerton, CA). Bilirubin and creatinine values were measured using either the Hitachi 7600 analyzer (Hitachi High-Technologies, Tokyo, Japan) or Toshiba 200FR (Toshiba Medical Systems, Tokyo, Japan).
INR Performance for Warfarin Monitoring
Determination of ISI WHO
The ISI WHO values of six thromboplastins were determined using the WHO reference method. 5 PT testing for each thromboplastin was performed using plasma samples from 60 warfarin-treated patients (24 men and 36 women; mean age, 65 years; age range, 32-86 years) and 20 healthy controls. A natural logarithm scaled plot compared the PT of reference thromboplastins on the vertical axis with the PT of the working thromboplastins on the horizontal axis. The ISI values of the working thromboplastins were defined as the slope of the orthogonal regression lines multiplied by the ISI of the reference thromboplastin. An acceptable coefficient of variation (CV) for the slope of calibration line was considered 3% or less.
Determination of Two Local ISIs (ISI localA , ISI localB )
Two local ISIs were defined using two commercial calibration kits, including local calibrator A (lot number N0302097, HemosIL ISI Calibrate; Instrumentation Laboratory) and local calibrator B (lot number 41662, PT-Multi Calibrator; Siemens Healthcare Diagnostics). We arbitrarily defined a local ISI determined by local calibrator A as "ISI localA ." Local calibrator A comprised four INR-certified lyophilized plasmas. The PTs of calibrant plasmas were tested in duplicate over 3 days using the ACL 3000 according to the CLSI guideline. 7 A log-scaled orthogonal regression line was generated by plotting certified INRs on the vertical axis, and the PTs were measured on the horizontal axis. 5 From the slope and y-intercept of the calibration line, the local ISI and MNPT were derived as follows: ISI = 1/slope, and MNPT = 10 y-intercept . 21 We also determined "ISI localB " by using local calibrator B, which has a set of six pooled lyophilized plasmas with certified INR values according to the method above. 5, 7, 21 
Validation of INR Consistency for Warfarin Monitoring
To evaluate the INR consistency among the six thromboplastins, we used plasma from 30 warfarinized samples (17 men and 13 women; mean age, 64 years; age range, 39-90 years), which were different from plasma samples used for the ISI calibration. MNPT for each thromboplastin was determined by calculating the geometric mean of the PT from 20 normal healthy controls. 14 Each INR was calculated from the assigned ISI and MNPT using the following equation: INR = (patient PT/MNPT) ISI .
INR Performance for Evaluation of Liver Disease
Measurement of Coagulation Factor Levels
Plasma levels of coagulation factors II, V, VII, and X, as well as fibrinogen, were measured in 45 patients treated with oral anticoagulation therapy and 45 patients with liver cirrhosis.
Determination of Liver-Specific ISI (ISI liver )
ISI liver values of the six thromboplastins were determined using 60 samples from patients with liver disease (35 men and 25 women; mean age, 52 years; age range, 33-88 years) and 20 healthy controls according to the WHO reference method, with some modification. 5 ISI liver of each thromboplastin was defined as the slope of the orthogonal regression lines multiplied by the ISI of the reference thromboplastin. 
Statistical Analysis
Statistical analysis was performed using MedCalc Statistical Software, version 12 (MedCalc Software, Mariakerke, Belgium) and SPSS, version 19 (SPSS, Chicago, IL). The variation in both ISI and INR values across six thromboplastins was estimated by calculating the percentage CV: [standard deviation/mean] × 100. The differences in the INR or MELD score between calibration methods were investigated using a paired t test. The difference in coagulation factor levels between clinical conditions was determined using an independent t test. P values less than .05 were considered statistically significant.
Results
INR Performance for Warfarin Monitoring
Differences in ISI Values
ISI values were calculated using four different methods and six commercial thromboplastins ( 
INR Performance for Evaluation of Liver Function
Differences in Coagulation Factor Levels in Terms of Clinical Conditions
Plasma levels of coagulation factors were investigated with regard to clinical conditions ❚Table 3❚. Fibrinogen level was lower in patients with liver disease than in those undergoing warfarin anticoagulation therapies. The levels of vitamin K-dependent coagulation factors (II, VII, and X) were markedly decreased in patients treated with warfarin anticoagulation therapy compared with patients with liver cirrhosis. However, the level of vitamin K-independent coagulation factor V was higher in patients undergoing warfarin anticoagulation therapy than in patients with liver cirrhosis.
Determination of ISI liver
When ISI liver values were determined, the CVs of the slope were acceptable (<3%) in the ISI liver of all six thromboplastins (Table 1 ). For Innovin, the ISI liver (0.99) was higher than the ISI WHO (0.85) but lower than the ISI uncorrected (1.02).
In the case of RecombiPlasTin 2G, there was no significant difference between the ISI liver and ISI uncorrected . In three rabbit brain thromboplastins, the ISI liver tended to be lower than the ISI uncorrected .
Differences in INRs for Patients With Liver Cirrhosis
The (Fig. 2A) , INR uncorrected showed more dispersion of INR values across six thromboplastins ( Figure 2B ). However, INR liver showed greater standardization than both INR WHO and INR uncorrected ( Figure 2C ).
Differences in MELD Scores in Patients With Liver Cirrhosis
The MELD scores were also calculated from the INRs of six thromboplastins in 16 calibration plasma samples from patients with liver cirrhosis ❚Table 5❚. The between-thromboplastin total CV of MELD liver (7.02) was significantly lower than that of MELD uncorrected (8.88 ) but similar to that of MELD WHO (7.01) . The between-thromboplastin human CV of MELD liver (4.25) was markedly lower than that of MELD uncorrected (10.27) . In addition, the betweenthromboplastin rabbit CV of MELD liver (5.79) showed a similar quality of standardization as MELD uncorrected (5.68), although it was superior to that of MELD WHO (7.20) .
Discussion
Since INR has been designed to standardize PT values to monitor therapeutic responses to warfarin therapy, it is important to yield a consistent INR result worldwide. 22 However, it has been shown that a major inconsistency in INR results from local variations in ISI values determined using different thromboplastins and coagulometers. Even the same thromboplastin and coagulometer combination may show some difference in ISI value. 5 Hence, to improve INR consistency, local ISI calibration has been recommended by using a local calibrator set with certified PT/INR values that are traceable to an international standard. 7 Since some commercial local calibrators have recently become available in clinical fields, there was a need to evaluate the performance of these commercial local calibrators. Our study demonstrated that local ISI values, calibrated by two commercial calibrators, improved INR standardization across six different thromboplastins compared with the uncorrected ISI provided by the manufacturer, although the local ISIs did not show better standardization than the ISI calculated by the WHO method. A previous study showed that local ISI calibration improved INR consistency. 23 However, the authors of that study used an ECAA calibrator, which is a local calibrator; in the WHO calibration method. Since this study focused on the variability of INR results among six different thromboplastins, the absolute ISI value calibrated with the WHO calibration method was not important to evaluate consistency in our results. Nonetheless, use of the real WHO reference thromboplastin may be considered for future study. Second, "like-to-like" calibration should be performed. 14 In other words, human-based thromboplastins should be locally calibrated using certified plasmas with PT/INR values that have been assigned with a human international reference preparation because species-specific artifacts may cause interference in the calibration procedure. However, since there was no available commercial local calibrator that included a rabbit-origin reference thromboplastin, we inevitably applied the local calibration of rabbit thromboplastins to two commercial local calibrators that had been assigned with a human reference thromboplastin. Therefore, our results tended to show relatively poor standardization of INR results for rabbit thromboplastins. In the future, it is expected that a commercial local calibrator assigned a rabbit-origin reference thromboplastin will be available. Third, this study focused only on INR consistency according to the thromboplastins, not the coagulometer, because one coagulometer was used. Future studies need to evaluate the effect of coagulometers on ISI calibration. In summary, the local ISI values (ISI localA and ISI localB ) calculated using two local calibrators showed better consistency among six thromboplastins than the manufacturerinformed ISIs (ISI uncorrected ). However, the local ISI values did not show better consistency than the ISI calculated by the WHO method (ISI WHO ) for warfarin monitoring. The plasma coagulation factor levels in the liver cirrhosis group were significantly different from those in the warfarin anticoagulation group. The alternative calibration, using calibration plasma samples from patients with liver cirrhosis instead of calibration plasma samples from patients on warfarin anticoagulation therapy, could reduce the variability in INR and MELD scores in patients with liver cirrhosis.
In conclusion, INR is better standardized using the WHO calibration method and commercial local calibrators compared with the uncorrected manufacturer-informed INR. Considering that the WHO calibration method is impractical in terms of availability despite its excellent performance, clinical laboratories can obtain relatively reliable INR values by adapting the commercial calibrator, which can be simply applied with lower cost and labor. In addition, the alternative calibration using liver-specific calibration plasma samples may reduce INR variability in patients with liver disease. However, the alternative calibration method requires liver-specific calibration plasma samples and significant labor in a clinical laboratory. It is expected that commercial calibrators for alternative liverspecific calibration will be developed in the future.
to reduce the INR variability more than the uncorrected INR. As demonstrated in previous studies, 20,24 different types of calibrators have different calibrating systems or calculating interfaces. Local calibrator A used four certified plasmas from the plasma of healthy donors or patients on stable warfarin therapy. The assigned INR value was in the range of 0.9 to 5.0. It was designed for HemosIL PT reagents (RecombiPlasTin 2G, PT-Fibrinogen HS Plus, and PT-Fibrinogen) on coagulometers from the Instrumentation Laboratory in conjunction with the ISI web software. Local calibrator B used six certified plasmas, which were derived from pooled plasma of healthy human donors and depleted pooled human plasma. The INR value, which was dependent on the PT reagent, was in the range of approximately 0.83 to 6.0. It was designed for Siemens reagents (Dade Innovin and Siemens Thromborel S) on coagulometers from Siemens. Therefore, further study is required to investigate the performance of commercial local calibrators with respect to their affiliated thromboplastins and coagulometers.
Although the INR is generally used to monitor warfarin therapy, 14 it has also been applied to the MELD score to assist in the prioritization of patients for liver transplantation. 18 INR showed a high imprecision and inaccuracy among the MELD components. 25 As mentioned in previous studies, [14] [15] [16] warfarin INR may be unsuitable for measuring coagulation status in patients with liver disease. For INR standardization in the evaluation of liver cirrhosis, it is important to understand the difference in coagulation factor levels in each clinical condition. Our study demonstrated that there was a large difference in coagulation factors between warfarin anticoagulation and liver cirrhosis ( Table 3) . As expected, vitamin K-dependent coagulation factors (II, VII, and X) were markedly decreased in the warfarin anticoagulation group, while a greater decrease in vitamin K-independent coagulation factors (fibrinogen and factor V) was observed in the liver cirrhosis group.
Since the thromboplastin reagents have different responsiveness to different levels of coagulation factors, 2 we attempted to investigate an alternative calibration that was specific for liver cirrhosis. We found that INR liver was more consistent than INR uncorrected , especially in human thromboplastin. However, in rabbit brain-derived thromboplastins, INR liver exhibited little improved consistency compared with INR uncorrected . INR standardization could be improved using an alternative ISI specific for liver cirrhosis by using calibration plasmas from patients with liver cirrhosis. Consistent with our result, previous studies have reported that alternative calibration using plasma samples from patients with liver cirrhosis was able to resolve INR variability between thromboplastins. 1, [26] [27] [28] This study has some limitations. First, we arbitrarily defined a commercial human recombinant thromboplastin (RecombiPlasTin 2G, lot number N0817013) instead of a WHO reference thromboplastin as a reference thromboplastin
